India is looking to regulate cell and gene therapies as drugs. The panel of experts will discuss their current proposed draft of Regulatory Guidelines on Gene and Cell Therapy Drugs as well as their experience of developing bio therapeutics, including early stage CAR-T companies in India. What can India learn from other countries’ regulations while taking into consideration general challenges that governments’ should be aware of during the process? What experiences can be shared from companies who are currently developing products in this space?

Session ID: 553007